The antiserum was produced against synthesized peptide derived from human PLCG1 around the phosphorylation site of Tyr1253. AA range:1221-1270

Phospho-PLC γ1 (Y1253) Polyclonal Antibody detects endogenous levels of PLC γ1 protein only when phosphorylated at Y1253.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SRyQQ

PLCG1

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1

PLCG1 ;
PLC1 ;
1-phosphatidylinositol 4 ;
5-bisphosphate phosphodiesterase gamma-1 ;
PLC-148 ;
Phosphoinositide phospholipase C-gamma-1 ;
Phospholipase C-II ;
PLC-II ;
Phospholipase C-gamma-1 ;
PLC-gamma-1

The protein encoded by this gene catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a cofactor and plays an important role in the intracellular transduction of receptor-mediated tyrosine kinase activators. For example, when activated by SRC, the encoded protein causes the Ras guanine nucleotide exchange factor RasGRP1 to translocate to the Golgi, where it activates Ras. Also, this protein has been shown to be a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008],

Catalytic activity:1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol.,cofactor:Calcium.,Domain:The SH3 domain mediates interaction with CLNK (By similarity). The SH3 domain also mediates interaction with RALGPS1.,Function:PLC-gamma is a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase.,PTM:The receptor-mediated activation of PLC-gamma-1 and PLC-gamma-2 involves their phosphorylation by tyrosine kinases in response to ligation of a variety of growth factor receptors and immune system receptors.,PTM:Ubiquitinated by CBLB in activated T-cells.,similarity:Contains 1 C2 domain.,similarity:Contains 1 EF-hand domain.,similarity:Contains 1 PH domain.,similarity:Contains 1 PI-PLC X-box domain.,similarity:Contains 1 PI-PLC Y-box domain.,similarity:Contains 1 SH3 domain.,similarity:Contains 2 PH domains.,similarity:Contains 2 SH2 domains.,similarity:Contains 3 PH domains.,subunit:Interacts with AGAP2 via its SH3 domain (By similarity). Interacts with phosphorylated LAT upon TCR activation. Interacts with the Pro-rich domain of TNK1 via its SH3 domain. Associates with BLNK, VAV1, GRB2 and NCK1 in a B-cell antigen receptor-dependent fashion. Interacts with CBLB in activated T-cells; which inhibits phosphorylation. Interacts with SHB. Interacts via its SH3 domain with the Arg/Gly-rich-flanked Pro-rich domains of KHDRBS1/SAM68. This interaction is selectively regulated by arginine methylation of KHDRBS1/SAM68. Interacts with INPP5D/SHIP1 and CLNK (By similarity). Interacts with RALGPS1. Interacts (via SH3 domain) with HEV ORF3 protein.,

Cell projection, lamellipodium . Cell projection, ruffle . Rapidly redistributed to ruffles and lamellipodia structures in response to epidermal growth factor (EGF) treatment. .

>>Inositol phosphate metabolism ;
>>Metabolic pathways ;
>>EGFR tyrosine kinase inhibitor resistance ;
>>ErbB signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>Calcium signaling pathway ;
>>Chemokine signaling pathway ;
>>NF-kappa B signaling pathway ;
>>HIF-1 signaling pathway ;
>>Phosphatidylinositol signaling system ;
>>Phospholipase D signaling pathway ;
>>Axon guidance ;
>>VEGF signaling pathway ;
>>Neutrophil extracellular trap formation ;
>>Natural killer cell mediated cytotoxicity ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>Fc epsilon RI signaling pathway ;
>>Fc gamma R-mediated phagocytosis ;
>>Leukocyte transendothelial migration ;
>>Neurotrophin signaling pathway ;
>>Inflammatory mediator regulation of TRP channels ;
>>Thyroid hormone signaling pathway ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Growth hormone synthesis, secretion and action ;
>>Parkinson disease ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Vibrio cholerae infection ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Shigellosis ;
>>Yersinia infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Glioma ;
>>Non-small cell lung cancer ;
>>Hepatocellular carcinoma ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Lipid and atherosclerosis